The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABT | +12.28% | +29.92% | +5.37% | +262,336% |
| S&P | +14.5% | +93.32% | +14.09% | +6,871% |
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
A list of high-yielding dividend stocks to consider buying now.
Get a list of current -- and potential future -- Dividend Kings and learn how to leverage these strong companies to build wealth.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.37B | 6.9% |
| Gross Profit | $6.34B | 16.8% |
| Gross Margin | 55.75% | 4.7% |
| Market Cap | $233.12B | 17.5% |
| Market Cap / Employee | $2.04M | 0.0% |
| Employees | 114K | 0.0% |
| Net Income | $1.64B | 0.2% |
| EBITDA | $2.85B | 14.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.95B | -0.5% |
| Accounts Receivable | $7.97B | 16.3% |
| Inventory | 7K | 2.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.93B | -1.6% |
| Short Term Debt | $507.00M | -68.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 17.75% | 10.2% |
| Return On Invested Capital | 13.47% | 2.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.55B | 8.3% |
| Operating Free Cash Flow | $2.05B | 4.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 14.76 | 17.21 | 17.01 | 16.75 | -51.70% |
| Price to Book | 4.93 | 4.82 | 4.85 | 4.61 | -8.62% |
| Price to Sales | 4.71 | 5.47 | 5.52 | 5.34 | 10.53% |
| Price to Tangible Book Value | 22.33 | 12.83 | 12.33 | 11.27 | -53.53% |
| Price to Free Cash Flow TTM | 73.25 | 78.52 | 84.22 | 84.99 | -8.46% |
| Enterprise Value to EBITDA | 78.91 | 73.31 | 97.55 | 85.78 | 12.61% |
| Free Cash Flow Yield | 1.4% | 1.3% | 1.2% | 1.2% | 9.24% |
| Return on Equity | 14.9% | 31.0% | 30.7% | 31.0% | 114.21% |
| Total Debt | $14.98B | $15.28B | $13.24B | $13.44B | -8.93% |
ABT earnings call for the period ending December 31, 2024.
ABT earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
